Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03738423
Registration number
NCT03738423
Ethics application status
Date submitted
8/11/2018
Date registered
13/11/2018
Date last updated
10/06/2022
Titles & IDs
Public title
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Query!
Scientific title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis
Query!
Secondary ID [1]
0
0
2018-001544-64
Query!
Secondary ID [2]
0
0
R3500-AD-1805
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - REGN3500
Treatment: Drugs - REGN3500-Matching Placebo
Experimental: Treatment 1 -
Experimental: Treatment 2 -
Experimental: Treatment 3 -
Experimental: Treatment 4 -
Experimental: Treatment 5 - Matching placebo
Treatment: Drugs: REGN3500
Administered subcutaneous (SC)
Treatment: Drugs: REGN3500-Matching Placebo
Administered subcutaneous (SC)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [1]
0
0
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 was reported. Values after first rescue treatment were set to missing.
Query!
Timepoint [1]
0
0
Week 16
Query!
Primary outcome [2]
0
0
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [2]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [=] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [1]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (=50% Improvement from baseline) at Week 16 were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [=] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [2]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (=50% Improvement from baseline) at Week 16 were based on all observed values regardless of rescue treatment were reported.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (=75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [3]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (=75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
Query!
Timepoint [3]
0
0
Week 16
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (=75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [4]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (=75% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.
Query!
Timepoint [4]
0
0
Week 16
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (=90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [5]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (=90% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
Query!
Timepoint [5]
0
0
Week 16
Query!
Secondary outcome [6]
0
0
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (=90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [6]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (=90% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.
Query!
Timepoint [6]
0
0
Week 16
Query!
Secondary outcome [7]
0
0
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [7]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported.
Query!
Timepoint [7]
0
0
Week 16
Query!
Secondary outcome [8]
0
0
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [8]
0
0
The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.
Query!
Timepoint [8]
0
0
Week 16
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of =2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [9]
0
0
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of =2 points at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing IGA score at Week 16 were counted as non-responders.
Query!
Timepoint [9]
0
0
Week 16
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of =2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [10]
0
0
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of =2 points at Week 16 based on all observed values regardless of rescue treatment were reported.
Query!
Timepoint [10]
0
0
Week 16
Query!
Secondary outcome [11]
0
0
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [11]
0
0
Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported.
Query!
Timepoint [11]
0
0
Week 16
Query!
Secondary outcome [12]
0
0
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [12]
0
0
Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Timepoint [12]
0
0
Week 16
Query!
Secondary outcome [13]
0
0
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [13]
0
0
Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.
Query!
Timepoint [13]
0
0
Week 16
Query!
Secondary outcome [14]
0
0
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [14]
0
0
Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.
Query!
Timepoint [14]
0
0
Week 16
Query!
Secondary outcome [15]
0
0
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS Score =4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Query!
Assessment method [15]
0
0
Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS score =4 from baseline to Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.
Query!
Timepoint [15]
0
0
Week 16
Query!
Secondary outcome [16]
0
0
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Daily Peak Pruritus NRS Score =4 Based on All Observed Values Regardless of Rescue Treatment at Week 16
Query!
Assessment method [16]
0
0
Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS score =4 from baseline to Week 16 based on all observed values regardless of rescue treatment were reported.
Query!
Timepoint [16]
0
0
Week 16
Query!
Secondary outcome [17]
0
0
Time to Onset of Effect on Pruritus (=4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)
Query!
Assessment method [17]
0
0
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?"
Query!
Timepoint [17]
0
0
Week 16
Query!
Secondary outcome [18]
0
0
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16
Query!
Assessment method [18]
0
0
The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [18]
0
0
Week 16
Query!
Secondary outcome [19]
0
0
Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16
Query!
Assessment method [19]
0
0
BSA affected by AD will be assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined. The proportion assigned to different body regions is different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children).
Query!
Timepoint [19]
0
0
Week 16
Query!
Secondary outcome [20]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 16
Query!
Assessment method [20]
0
0
Adverse Event (AE): any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE): any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included: serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic or acute allergic reactions; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; severe infections; any clinical endoparasitosis; Conjunctivitis, keratitis, or blepharitis; significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 16 were reported.
Query!
Timepoint [20]
0
0
Up to week 16
Query!
Secondary outcome [21]
0
0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 36
Query!
Assessment method [21]
0
0
AE: any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. SAE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included both Serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic or acute allergic reactions; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; severe infections; any clinical endoparasitosis; Conjunctivitis, keratitis, or blepharitis; significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 36 were reported.
Query!
Timepoint [21]
0
0
Up to week 36
Query!
Secondary outcome [22]
0
0
Serum Concentration of Functional REGN3500
Query!
Assessment method [22]
0
0
Serum Concentration of Functional REGN3500 was reported.
Query!
Timepoint [22]
0
0
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32 and 36
Query!
Secondary outcome [23]
0
0
Number of Participants With Positive Treatment-Emergent Anti-REGN3500 Antibodies (ADA)
Query!
Assessment method [23]
0
0
Treatment-Emergent (TE) ADA was defined as any positive post baseline assay response when baseline results were negative or missing. Treatment-Emergent ADA responses were further classified as: - persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period [based on nominal sampling time], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point),- indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), - transient (not persistent/indeterminate, regardless of any missing samples). Number of participants with positive treatment-emergent anti-REGN3500 antibodies (ADA) were reported. Here, "Number of Participants Analyzed" signifies those participants who were evaluable for this endpoint.
Query!
Timepoint [23]
0
0
Up to week 36
Query!
Eligibility
Key inclusion criteria
Key
1. Chronic AD, according to American Academy of Dermatology Consensus Criteria
(Eichenfield, 2014), that has been present for at least 3 years before the screening
visit
2. Eczema Area and Severity Index (EASI) score =16 at the screening and baseline visits
3. IGA score =3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe) at
screening and baseline visits
4. =10% Body surface area (BSA) of AD involvement at the screening and baseline visits
5. Documented recent history (within 6 months before the screening visit) of inadequate
response to topical AD medication(s) or for whom topical treatments are medically
inadvisable
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participation in a prior anti-Interleukin (IL)-33 medication clinical study
2. Treatment with an investigational drug within 8 weeks or within 5 half-lives (if
known), whichever is longer, before the baseline visit
3. Having used any of the following treatments within 4 weeks before the baseline visit
or any condition that, in the opinion of the investigator, is likely to require such
treatment(s) during the first 4 weeks of study treatment:
1. Immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids,
cyclosporine, mycophenolate-mofetil, Interferon-gamma (IFN-?), Janus kinase
inhibitors, azathioprine, methotrexate, etc)
2. Phototherapy for AD
4. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of
the baseline visit
5. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit
6. Active chronic or acute infection requiring treatment with systemic antibiotics,
antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the
baseline visit
7. Known or suspected history of immunosuppression
8. History of human immunodeficiency virus (HIV) infection or positive HIV serology at
screening
9. Positive with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb),
or hepatitis C virus antibody (HCV Ab) at the screening visit
10. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
during the study
Note: Other protocol defined Inclusion/Exclusion Criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/11/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
129
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Regeneron Study Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Regeneron Study Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
3002 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nevada
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Hampshire
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oklahoma
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Alberta
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Ontario
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Quebec
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Brno
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Nachod
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Ostrava
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Praha
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Bad Bentheim
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Berlin
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Frankfurt
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Hamburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Hanau
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Ibbenburen
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Leipzig
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Lubeck
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Munchen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Munster
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Tubingen
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Tuebingen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Witten
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Bekes
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Hajdu-Bihar
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Chuo
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Hiroshima
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Kanagawa
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kyoto
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Shizuoka
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Wakayama
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Yamanashi
Query!
Country [52]
0
0
Korea, Republic of
Query!
State/province [52]
0
0
Bucheon-Si
Query!
Country [53]
0
0
Korea, Republic of
Query!
State/province [53]
0
0
Busan
Query!
Country [54]
0
0
Korea, Republic of
Query!
State/province [54]
0
0
Gyeonggi-do
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Incheon
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Seoul
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Krakow
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Lodz
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Szczecin
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Warszawa
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Wroclaw
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Barakaldo
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Cordoba
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Madrid
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Santiago de Compostela
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Regeneron Pharmaceuticals
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Sanofi
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in
Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with
placebo treatment, in adult patients with moderate-to-severe AD.
Secondary objectives are to:
- Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 monotherapy in
adult patients with moderate-to-severe AD
- Assess the Pharmacokinetics (PK) of REGN3500 in adult patients with moderate-to-severe
AD
- Assess the immunogenicity of REGN3500 in adult patients with moderate-to-severe AD
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03738423
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trial Management
Query!
Address
0
0
Regeneron Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03738423
Download to PDF